Transcript Highlights:

• So can you commit to applying CDC, FDA standards when a...
• And one example is something called Essure, which was FDA approved.
• And is that approved by the FDA?
• FDA, to my knowledge, is not yet FDA, to my knowledge, has not yet explored what Dr.
• I'm very concerned about your not wanting to follow FDA and CDC guidelines.

Summary: The committee first considered the confirmation of Dr. John Lattell to the Board of Medicine. In questioning, senators focused heavily on his views about abortion, vaccines, ivermectin, and the role of CDC/FDA guidance in board discipline cases. Dr. Lattell said the board applies Florida statutes and works through probable cause panels and legal counsel, but he also expressed strong pro-life views, skepticism of federal health guidance, and criticism of vaccines and some medical practices. Supporters praised his long medical career, military service, and family medicine background, while opponents argued his views could prevent him from being objective in disciplinary matters. The committee voted to recommend him for confirmation to the full Senate, with Senators Polsky and Ruson voting no. The committee then took up the confirmation of Taylor Hatch as Secretary of the Department of Children and Families. Hatch described her background in state human services and outlined priorities centered on accountability, data, lived experience, and improving service delivery. Senators asked about SNAP error rates, Hope Florida, legislative analyses, staffing, and the department’s handling of child welfare and medically complex cases. Hatch said the department was reducing SNAP error rates, that Hope Florida uses navigators to connect people with community resources and self-sufficiency supports, and that DCF is working with the Department of Health and other partners to improve investigations and accountability in child welfare. She also said the agency is reviewing medically complex cases and strengthening oversight of community-based care providers through contracts, audits, and proposed funding-model changes. A substantial portion of the Hatch discussion centered on whether the department had been responsive to legislative requests and whether it had provided timely bill analyses. Senators also pressed her on Hope Florida staffing, the number of participants served, and the Hope Florida Foundation’s compliance and legal oversight. Hatch said the foundation is undergoing a financial audit and that the department is relying on required reports and ongoing investigations. The transcript ends amid continued questioning about a community-based care contractor’s finances, related-party transactions, and whether further forensic audits or repayments are needed.

Transcript Highlights:

• <00:14:21.519> uh FDA warning uh FDA warning uh tries<00:14:24.240> to<00:14:24.320>
• Um the FDA is as physical dependence.
• Uh the FDA to toratum prior to birth.
• <00:16:37.120> Recent<00:16:37.519> FDA ...overdoses and deaths.
• The FDA has identified than morphine.

Bills: HB0103, HB0070, HB0091

Keywords: First Amendment, free speech, lawsuits, immunity, public participation, strategic lawsuits, foreign censorship, digital innovation, constitutional rights, Wyoming GRANITE Act, extraterritorial laws, civil actions, speech protection, legal jurisdiction, joint liability, artificial intelligence, social scoring, biometric data, privacy rights, government regulation

Transcript Highlights:

• I am presenting SB 950, which will ensure timely access to FDA-approved, medically necessary treatments
• These treatments approved by the FDA present a paradigm shift for those contending with an Alzheimer's
• It aligns California with FDA clinical evolution and Medicare policy.
• SB 1094 would allow pharmacists to substitute FDA-approved biosimilars unless the prescriber indicates
• you are FDA-approved, you are basically the same as the reference product.

Keywords: 988, house, all

Transcript Highlights:

• :46.159> there Unlike FDA approved medications, there Unlike FDA approved medications, there is
• The FDA has issued indefensible.
• <02:02:52.000> review appropriate pathway is FDA review appropriate pathway is FDA review
• We have FDA warnings and we have some action that the FDA has taken, but the federal government has not
• The FDA has issued multiple times.

Keywords: 1191, senate, all

Transcript Highlights:

• established by the FDA. established by the FDA.
• FDA. FDA.
• product, and then a link to the US FDA product, and then a link to the US FDA website<01:51:36.520
• established by the US FDA. established by the US FDA.
• So, um in fact, the FDA<01:57:49.640> has<01:57:50.640> um FDA has um FDA has um they<01

Keywords: 927, senate, all

Transcript Highlights:

• SB 964 would allow dose or frequency increases without confirming they align with FDA study dosing or
• labeling and applicable FDA guidance.
• So specifically as a GI doctor, the medications, when they're being FDA approved at the time that they
• And it's very, very difficult for us to get these medications approved by FDA.
• And it's very, very difficult for us to get these medications drug approved by FDA.

Keywords: 988, house, all

Summary: The Assembly Health Committee heard several bills focused on health care access, insurance coverage, public health, and patient protections. SB 1023 by Senator Laird would require insurers that cover injectable PrEP under the medical benefit to also cover it under the pharmacy benefit, to reduce billing barriers and improve access to HIV prevention. Supporters included HIV/AIDS organizations, the Department of Insurance, medical groups, and LGBTQ advocates; health plans opposed the bill as an unnecessary benefit-design mandate. The committee later voted the bill out on a due pass motion, and it remained on call before being finalized out later in the hearing. SB 964 by Senator Smallwood-Cuevas would limit repeated prior authorization requirements when a clinician needs to adjust the dose or frequency of a covered medication for a patient with a chronic or complex condition, with safeguards for off-label use and controlled substances. Support came from physicians, hospitals, and patient advocates, especially in gastroenterology and chronic disease care, while insurers argued it weakened safety and utilization-management safeguards. The committee approved the bill on a due pass vote to Appropriations. SB 1323 by Senator Rubio, as amended in committee, would strengthen protections for patients receiving medical care while in immigration custody by requiring facilities to train staff on responding to such requests and allowing patients to notify a family member or loved one of their location. It passed the committee on a due pass as amended vote to Judiciary, with one no vote recorded. SB 1099 by Senator Reyes would clarify local governments’ authority to provide state and local public benefits to all residents under the federal PRWORA exemption, giving cities and counties more certainty when operating low-barrier services such as health care, shelter, crisis response, and homeless outreach. Local government attorneys and service providers supported the measure, and there was no opposition testimony; it passed to Human Services. SB 895 by Senator Wiener would place a $12 billion science research bond on the November ballot and create a state research funding institute to help sustain California’s research economy amid federal cuts. The bill drew broad support from universities, labor, health organizations, patients, and business groups, with one member voting no because of the bond cost; it passed to Appropriations. SB 944 by Senator Wiener would stabilize Medi-Cal coverage for acupuncture, which supporters described as a cost-effective, nonpharmacological treatment for pain and other conditions. It passed to Appropriations with strong support and no opposition testimony. At the end of the hearing, the committee also took add-on votes to confirm the bills’ passage status and adjourned.

Transcript Highlights:

• During the COVID-19 pandemic, the FDA and CDC advised against using ivermectin to treat COVID.
• Can you commit to applying CDC and FDA standards? Senator Polsky: I disagree.
• And one example is something called Essure, which is FDA approved.
• At the FDA, approval was done without any research at all.
• I'm very concerned about you not wanting to follow FDA and CDC guidelines.

Keywords: 999, senate, all

Transcript Highlights:

• Now the FDA, which has very lax rules, but even under the FDA's rules, they...
• But here's what used to be required by the FDA.
• FDA.
• FDA studies.
• Clearly, the FDA should immediately reinstate the procedures that were in place.

Bills: SB 2, SB 5, SB 10, SB 9, SB 7, SB 17, SB 4, HB17, HB7, HB7, HB15, HB15, HB27, HB1, HB7, HB15, HB18, SB9, SB7, SB17, SB4, HB17, HB27, HB1, SB8, HCR13, SB2, SB5, SB10

Keywords: disaster relief, flood preparedness, emergency funding, local government support, meteorological forecasting, school assessment, public education, accountability, transparency, education standards, STAAR, Texas Education Agency, TEA, public school accountability, school ratings, A-F ratings, assessment reform, student testing, benchmark tests, interim assessments

Transcript Highlights:

• If it's not authorized by the FDA, it's off the shelf in Texas.
• I'm also an FDA regulatory consultant.
• So, I do FDA work every day, so if you have FDA PMTA questions, I'm your person.
• The FDA has only authorized about 10 unique vaping products.
• The FDA denied my applications for bottled e-liquid back in 2021.

Bills: SB30, SB517, SB1313, SB1314, SB1316, SB1541, SB1698, SB1845, SB1860, SB2420, SB2429, SB 30

Keywords: gambling, criminal offenses, penalties, defense, electronic devices, tobacco advertising, youth protection, public health, criminal offense, retailer regulation, e-cigarettes, nicotine products, health, public safety, regulation, advertising restrictions, health and safety, elections, election audit, county elections

Transcript Highlights:

• They do have applications for modified risk tobacco products with the FDA now.
• They have yet to be evaluated by the FDA in completion.
• Claims about the FDA no longer having authority or the FDA having safe harbor for products in pending
• No, we have direct statements from the FDA, the Center for Tobacco Products.
• I've been approved by the FDA, and then so you get a quick overview.

Transcript Highlights:

• /c><01:02:13.840> of approved by the FDA as the FDA kind of approved by the FDA as the FDA kind
• And you know, at AAFCO by AAFCO and FDA.
• And you don't need us to take any other action for them to do it as long as it's federal FDA.
• be fine with it as long as it's FDA be fine with it as long as it's FDA approved.<01:06:09.040><
• <01:07:52.400> Oh other agencies you know, maybe FDA Oh other agencies you know, maybe FDA

Bills: SB3302, SB2061, SB2050, SB2102, SB2694, SB2089, SB847

Keywords: SB3302, homemade food products, farm kitchens, home kitchens, Department of Health, DOH, food safety, food labeling, value-added agriculture, small farms, agricultural land, commercial food establishment permit, cottage food, direct-to-consumer sales, local food systems, Hawaii Revised Statutes, chapter 91, farm-to-table, food processing, public health regulation

Summary: The committee on Consumer Protection and Commerce met on April 9, 2026, and heard testimony on several measures. SB 3302 SD1 HD1, dealing with homemade food products, would require the Department of Health to adopt rules for farm kitchens producing homemade food products that are no more stringent than rules for home kitchens. The Department of Health said it supported the bill with technical amendments, and the Hawaii Food Industry Association and Grassroot Institute of Hawaii also supported it. No opposition was heard. A lengthy discussion focused on SB 2061 SD2 HD1, which concerns a 99-year leasehold residential condominium project and HCDA’s rules for sales, income restrictions, and buyback pricing. HCDA supported the bill and said the House draft clarified unclear provisions and would help move the project to pre-sales. Testimony and committee questions centered on whether the project should remain owner-occupied in perpetuity or allow investor purchases after an initial sales period. HCDA explained that the bill was revised to make the project feasible in the market, that 60% of units would be income-restricted for buyers at or below 140% of area median income, and that the remaining units could be sold without owner-occupancy restrictions. Some members and testifiers expressed concern that the bill had shifted away from the original owner-occupancy vision and could become an investment property model, while others argued the changes were necessary for the project to pencil out and compete with fee-simple developments. No vote was taken during the discussion shown. The committee also heard SB 2050 SD1 HD1, which would allow chiropractic students in accredited programs to engage in clinical practice beginning July 1, 2028. The Hawaii Board of Chiropractic and the Hawaii State Chiropractic Association supported the measure, and one testifier described personal experience with student chiropractic care in California. Members questioned why the board requested delaying implementation until 2030, and the board said it needed more time to develop rules because it meets only a few times a year and rulemaking is lengthy. Finally, SB 2102 SD2 HD1, on industrial hemp in commercial feed, was introduced; the Department of Agriculture and Biosecurity offered comments, the Department of Health raised concerns about regulating pet food and possible jurisdictional conflict, and a farmer testifying in support suggested narrowing the bill to federally approved livestock feed rather than pet food.

Transcript Highlights:

• The next three FDA reasons should make this committee's blood run cold. Fluoride consumption...
• Next, moving to S. 1497, an act protecting patient safety regarding non-FDA approved drugs.
• Next, moving to S1497, an act protecting patient safety regarding non-FDA approved drugs.
• to dispense drug products compounded by FDA-registered outsourcing facilities.
• The FDA agrees.

Keywords: 995, all

Summary: The Joint Committee on Public Health held a hearing focused on children’s health, disease prevention, screening, treatment, and pharmacy-related bills. The chair explained that the session was for public testimony only, with no votes or decisions taken that day, and outlined the three-minute limit for individual testimony. The committee then heard testimony on a range of bills, including H. 2413 on adding electromagnetic sensitivity to the state’s MAVEN registry, S. 1508 and H. 2433 on creating an amputation prevention task force, H. 2535 and S. 1551 on establishing a naloxone purchase trust fund, S. 1635 on authorizing pharmacists to provide opioid use disorder treatment, H. 2385 on creating a special commission on avian influenza, and S. 1497 on patient safety and non-FDA-approved compounded drugs. Testimony on H. 2413 came largely from advocates and individuals who described electromagnetic sensitivity as a real health condition and argued that adding it to the registry would improve data collection, provider education, and public awareness. Testimony on the amputation prevention task force bills came from the American Diabetes Association and podiatry groups, who said diabetes-related amputations are often preventable, disproportionately affect people of color, and could be reduced through earlier screening, better care coordination, and improved insurance coverage for preventive foot care. On the naloxone trust fund bills, a representative, emergency physician, and nurse testified that hospitals often cannot reliably send overdose patients home with naloxone because of billing and reimbursement barriers, and that a bulk-purchase fund would expand access at no added cost to payers or providers. The committee also heard strong support for S. 1635 from pharmacists and public health researchers, who said community pharmacists could safely initiate and maintain buprenorphine treatment and help close gaps in opioid use disorder care. On H. 2385, a local board of health chair supported a special commission on avian influenza, citing gaps in emergency preparedness and the need for clearer coordination across agencies. On S. 1497, a pharmacy representative opposed restrictions on compounded drugs from outsourcing facilities, warning that changes could reduce access to life-saving medications and harm patient safety. No votes or formal actions were taken during the hearing.

Transcript Highlights:

• FDA that was scheduled or rescheduled.
• It's under FDA, but DEA, right?
• FDA that was scheduled or rescheduled.
• So what they're telling us, FDA that was scheduled or rescheduled.
• It's under FDA, but DEA, right?

Keywords: 1182, all

Summary: The committee heard a long series of Senate bills, mostly on third-read consent, covering education, public safety, health, courts, labor, and water. Several bills were briefly explained and then pulled from consent for further discussion, including measures on public records review standards (SB 1078), sexually explicit materials in schools/libraries (SB 1435 and SB 1567), burial costs in death cases (SB 1135), military flags in HOAs/COAs (SB 1184), court-ordered treatment guardianship (SB 1243), standardized state hiring (SB 1665), released-time religious instruction (SB 1741), firearm safety instruction in schools (SB 1424), student participation in extracurriculars after certain convictions (SB 1475), Celebrate Freedom Week (SB 1572), federal scholarship-granting organizations/vouchers (SB 1142), immigration-related arrest notifications (SB 1055), defamation standards (SB 1099), peace officer certification for military police veterans (SB 1107), mandatory reporting of child abuse/neglect directly to DCS (SB 1127), attorney licensing and discipline issues (SB 1148 and SB 1039), concealed weapons on college campuses (SB 1068), and firearm muffling devices/silencers (SB 1069). Members also raised constitutional, policy, and school-safety concerns on several of these bills, while supporters emphasized alternative pathways for students, veterans, and workers, and tighter reporting or licensing rules. Other bills were described without extended debate, including claims against the state for unpaid contracted services (SB 1097), workers’ compensation death benefits for surviving spouses who remarry (SB 1136), burial expense increases (SB 1135), state agency web pages for internal guidance (SB 1586), court-ordered treatment procedures and service of process in mental health cases (SB 1113), medical examiner authorization (SB 1123), tribal MOUs with DCS (SB 1125), controlled-substance scheduling conformity with federal classifications (SB 1188), EMT personal information protections (SB 1193), mammography notice updates (SB 1318), assisted-living referral disclosures (SB 1477), accommodation school GED instruction for 11th graders and students over 16 (SB 1166), credit enhancement board continuation (SB 1422), school district and charter school obligations related to religious release time (SB 1741), school firearm safety instruction (SB 1424), and school civics/freedom-week instruction (SB 1572). The committee also heard bills on CPA certification pathways (SB 1181), insurance adjuster licensing (SB 1415), county voter-registration rules online (SB 1040), campaign address privacy (SB 1259), federal land acquisition notification (SB 1281), water supply/demand assessments (SB 1202), environmental compatibility for power plants and small modular reactors (SB 1418), and groundwater recovery rules (SB 1785). The meeting ended with announcements and a brief recognition of Rep. Stephanie Hamilton with an “Affordability Award.” No final votes are shown in the transcript excerpt; instead, many bills were either left on consent, pulled for later discussion, or flagged for closed caucus. The chair then asked guests to leave so members could hold a closed caucus.

Transcript Highlights:

• They were added after they were approved by the FDA.
• They were added after they were approved by the FDA.
• <00:05:50.720> between these were approved by the FDA between these were approved by the FDA
• A small number are used for other FDA A small number are used for other FDA approved<00:10:22.720
• preparations were approved by the FDA preparations were approved by the FDA for<00:19:14.320>

Keywords: 958, all

Summary: The Medicaid Oversight and Advisory Board met on February 23, 2026, approved the January 12 minutes, and then focused primarily on Kentucky Medicaid’s coverage and potential expansion of GLP-1 drugs, especially for weight loss. Department for Medicaid Services Commissioner Lisa Lee explained that Medicaid currently does not cover drugs for weight loss, anorexia, or weight gain, but the department had filed a regulation to remove that blanket exclusion so GLP-1s could be covered when used for an underlying health condition. She said the administrative regulation review subcommittee found the regulation deficient, and the co-chairs wanted the board to discuss the policy and financing implications before any change. DMS also said it would be open to adding caveats to ensure coverage would not extend to cosmetic weight loss alone. The department provided several data points on current utilization and spending. In 2025, Kentucky Medicaid paid for appetite-stimulating drugs such as Megestrol, Dronabinol, and Marinol, but did not pay for weight-loss drugs. For GLP-1s, DMS said coverage began in 2025 and is limited to FDA-approved medical conditions, with prior authorization requiring a type 2 diabetes diagnosis code and A1C documentation. DMS reported $234.6 million in GLP-1 spending in 2025 before rebates, about 240,931 prescriptions, and said GLP-1s accounted for 7.3% of pharmacy spend in 2024 and 8.3% in 2025. It also said there were 24,844 expansion members and 13,638 non-expansion members using GLP-1s, with spending of about $156 million and $78.5 million respectively, and that 10 pediatric weight-loss prescriptions were covered under EPSDT. The department said outcome analyses, including whether GLP-1 use reduces insulin or other diabetes treatment, are underway and should be completed in a couple of months. Members asked about cost, rebates, and whether the state should wait for more outcomes data before expanding coverage. DMS said average reimbursement to pharmacies was $975 per prescription and the average dispensing fee was $109; it also said 2025 rebate invoices totaled $90.8 million, with $7.6 million collected so far. Several members expressed concern about the high cost and the need to evaluate whether the drugs improve health outcomes before expanding access, while others noted the potential benefits for obesity and diabetes treatment. Some members also discussed whether GLP-1s are effectively being used for weight loss in diabetic patients and whether broader data collection should be used to assess long-term value. After the Medicaid discussion, Eli Lilly executive Tracy Sims presented on obesity as a chronic disease and the economic burden it creates in Kentucky. She said Kentucky’s adult obesity rate is a little over 37%, that obesity is linked to about 200 diseases, and that untreated obesity costs the state billions in GDP and hundreds of millions in state budget impact. She highlighted recent federal access programs for GLP-1s, including a Medicaid-related program that she said could lower the state share of a Zepbound prescription to about $71 per month after federal matching. No votes were taken on the GLP-1 policy question during the meeting, and the main action was the receipt of testimony and discussion of the department’s proposed regulatory change.

Transcript Highlights:

• Junior, who runs FDA, Health and Human Services and FDA.
• I, you know, asked him if we needed something from the FDA to fast-track it.
• The FDA has approved dormectin for cattle.
• Last week by the FDA for use in cattle. For new world screwworm. Yes, sir. Okay.
• These must be FDA approved.

Keywords: 1184, house, all

Transcript Highlights:

• I am presenting SB 950, which will ensure timely access to FDA-approved medically necessary treatments
• The disease-modifying treatments approved by the FDA present a paradigm shift for those contending with
• SB 1094 would allow pharmacists to substitute FDA-approved biosimilars unless the prescriber indicates
• , The federal government has essentially said, and I’ll read a statement from the FDA: “All biological
• you are FDA-approved, you are basically the same as the reference product.

Summary: The Assembly Health Committee heard several measures, beginning with SB 331 by Sen. Menjivar, which would require large-group health plans to cover hearing aids for children. The author and supporters described the bill as a long-running effort to address a developmental emergency and reduce out-of-pocket costs for families, while opponents were absent. Testimony from parents, advocates, medical experts, and organizations emphasized the importance of early access to hearing aids; committee members voiced strong support, and the bill was moved on a do-pass basis to Appropriations, with several members requesting to be added as coauthors. The committee then heard SB 608, also by Sen. Menjivar, to expand access to condoms in school-based health centers and related settings and to prevent barriers such as ID checks. Supporters, including students and school health advocates, argued the bill would improve sexual health and reduce stigma, while opponents from family and faith groups argued it would undermine parental authority and normalize early sexual activity. The bill was supported by committee members and moved forward on a do-pass basis to Appropriations. Next, SB 971 by Sen. Choi proposed community-based healthy aging partnerships for older adults, with testimony from the California Senior Legislature and supporters from aging and dementia organizations. The measure was described as voluntary and focused on connection, independence, and local collaboration; there was no opposition, and the committee moved it on a do-pass basis to Appropriations. The committee also heard SB 869 by Sen. Weber Pierson, which would require warning icons and statements on chain restaurant menus for beverages with very high added sugar content. Supporters framed it as a transparency and public health measure, while restaurant and beverage industry representatives opposed it unless amended, citing cost and menu-space concerns; the bill was nevertheless moved on a do-pass basis to Appropriations after a roll call vote, with some members voting no and the measure placed on call. The committee also considered SB 950 by Sen. Weber Pierson, aimed at ensuring timely coverage of FDA-approved, medically necessary treatments for early-onset Alzheimer’s disease on commercial plans. Supporters, including the Alzheimer’s Association and a patient advocate, said the bill would reduce delays and barriers to care, while health plan representatives opposed it over step therapy and utilization-management concerns. Members discussed the limited treatment window and the need for early access, and the bill was moved on a do-pass basis to Appropriations. In addition, SB 490 by Sen. Umberg would set timelines for DHCS investigations of unlicensed sober living homes and allow counties to assist if the department cannot act in time; supporters from Anaheim and a patient-brokering survivor described serious abuse and oversight gaps, while county behavioral health representatives opposed the county role as an unfunded and potentially liability-creating burden. After discussion, the bill was also moved on a do-pass basis to Appropriations. Finally, the committee began hearing SB 1037 by Sen. Weber Pierson on health insurance affordability and rate review, with supporters arguing it would tie premium increases more closely to affordability targets and public reporting; the transcript cuts off before the committee completed action on that measure.

Transcript Highlights:

• three that would allow that if the FDA three that would allow that if the FDA adopts<02:11:16.480
• price if we adopt this and if the FDA price if we adopt this and if the FDA makes<02:12:01.800><
• When I reviewed the comments on the FDA, the potential change in FDA guidance, where all you would need
• when I reviewed the comments on the FDA when I reviewed the comments on the FDA the<02:14:37.920
• actions at the federal level or if FDA actions at the federal level or if FDA takes<02:28:02.800

Keywords: 1189, house, all

Transcript Highlights:

• labeling and applicable FDA guidance.
• We start with the FDA-approved dose, which goes through the first prior authorization.
• Because there is only one drug, which was FDA approved all these years for pediatrics, and only this
• And it's very, very difficult for us to get these medications approved by FDA.
• The research has advanced beyond the initial FDA studies, and in practice, it's much more helpful to

Summary: The Assembly Health Committee heard several bills on June 9. SB 1023 by Senator Laird would require insurers that cover injectable HIV PrEP under the medical benefit to also cover it through the pharmacy benefit, with supporters saying the change would reduce reimbursement delays and expand access, while health plans opposed it as an unnecessary mandate that interferes with benefit design. SB 964 by Senator Smallwood-Quivas would limit prior authorization for certain dose or frequency adjustments to covered medications, especially for chronic complex conditions; medical supporters said it would prevent harmful delays in care, while insurers argued it weakens safety and utilization controls. SB 1323 by Senator Rubio, as amended, would strengthen protections for people in immigration custody receiving medical care by requiring hospitals and facilities to inform staff how to respond to requests and allowing patients to notify family members of their location; it passed with one no vote. SB 1099 by Senator Reyes would clarify local governments’ authority to provide state and local public benefits to all residents under federal PRWORA rules, with supporters saying it would reduce legal uncertainty for safety-net services; it passed, though one member later changed a vote to no on the add-on roll call. The committee also took up SB 895 by Senator Wiener, a proposed $12 billion science research bond for the November ballot that would create a California scientific research funding institute. Supporters from UC, UAW, hospitals, and advocacy groups said the measure would help offset federal cuts, protect research jobs, and sustain California’s leadership in biomedical and other research; there was no opposition, and the bill passed on a party-line style vote with two no votes. SB 944, also by Senator Wiener, would stabilize Medi-Cal coverage for acupuncture, which supporters described as a cost-effective, non-pharmacological treatment for pain and other conditions that has repeatedly been threatened in the budget process; it passed unanimously. The committee also approved consent items SB 918 and SB 1202, and later cleared the remaining measures on call after roll votes and add-on votes were taken.

Transcript Highlights:

• Does that include notification that what they are receiving is not FDA approved? Senator Trumbull.
• How will the state monitor the outcomes and the safety for patients who receive this non-FDA-approved
• getting an unregulated treatment versus a regulated therapy, a therapy that’s been approved by the FDA
• Or is this going to open the door for vulnerable... ...that’s been approved by the FDA?
• And I think it is a—I do need to clarify that currently the stem cells are FDA approved.

Summary: The Appropriations Committee on Health and Human Services met to consider a full agenda of bills, moving quickly through 20 measures and several amendments. Early bills reported favorably included SB 976 on procedures for challenging court-appointed psychologists in family law cases, SB 306 on Medicaid managed care provider access outside regular business hours, and SB 584 on housing supports for foster youth and college students, which drew supportive testimony from former foster youth and was backed by members as a way to improve stability and educational opportunity. The committee also approved SB 1412 to modernize home health regulations and SB 1800 to create a Parkinson’s research consortium at USF, with members citing the need for more research and future funding opportunities. The committee adopted amendments on several bills, including technical and conforming changes to the Parkinson’s bill and other measures. The committee then advanced a series of health care and child welfare bills. SB 524 added Duchenne muscular dystrophy to newborn screening; SB 1156 revised the Home Health Aide Program for medically fragile children, including training, reimbursement, and work-hour flexibility; and SB 1490 reorganized services for medically fragile children by shifting program administration to AHCA and requiring a redesign plan for the Medicaid waiver. SB 1174 allowed foster home and child-caring agency licenses to be amended when a foster parent relocates, and SB 1620 implemented selected recommendations from the Commission on Mental Health and Substance Use Disorders, including a new research center at USF and school-based behavioral health review requirements. SB 1568 revised e-prescribing exemptions, and SB 78 authorized certain veterans’ nursing home beds and related certificate-of-need transfers. All of these measures were reported favorably after brief debate or supportive testimony. Several bills prompted more extensive discussion and some opposition. CS for CS SB 1270, the Department of Health agency package, included provisions on vaccination-related patient rights, medical marijuana reporting, background screening, temporary licensure, compact participation, and sovereign immunity for volunteer dentists; it passed despite concerns from Senators Berman, Brodeur, and Harrell about vaccination language and board/voting-power provisions. CS for SB 1606 on patient access to records drew strong opposition from physicians and health information professionals over privacy, security, fines, and portal access; it was initially reported unfavorably, then reconsidered and ultimately reported favorably as a committee bill. CS for SB 1736, allowing insulin administration by direct support professionals and relatives for individuals with developmental disabilities, and SB 1808, requiring timely refunds to patients, both passed. CS for SB 1842, requiring referring providers to help patients determine whether referred providers are in-network, also passed over concerns about burden on small practices. The committee also advanced SB 1354, a behavioral health oversight bill requiring audits, performance reporting, and system transparency measures for managing entities, and SB 1768, which authorizes physicians to perform certain stem cell therapies using specified products and requires informed consent; both drew supportive comments but also concerns about patient understanding and oversight. Finally, the committee approved SPB 7032 as a committee bill to create presumptive Medicaid eligibility for permanently disabled individuals during redetermination, and after reconsideration it reported SB 1606 favorably as a committee bill. The meeting ended with members noting their recorded votes on select tabs and adjourning after completing the agenda.

Transcript Highlights:

• So, this is current FDA regulations.
• It's 361 of FDA standards.
• It's 361 of FDA 351<00:49:12.000> is<00:49:12.240> manipulated<00:49:12.960> and
• FDA.
• FDA.

Bills: HB0028, HB0080

Keywords: sexual exploitation, child protection, law amendment, explicit conduct, sex crimes, identification cards, nursing facilities, assisted living, renewal process, resident rights, 916, all